A deadline is coming up on June 13, 2016 in the settlement reached in the securities class action lawsuit filed on behalf of investors who purchased NASDAQ: MDCO shares between January 8, 2013 and February 12, 2014.
Investors who purchased a significant amount of shares of The Medicines Company (NASDAQ: MDCO) between January 8, 2013 and February 12, 2014, have certain options and should contact the Shareholders Foundation by email at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The settlement proof of claim form or detailed settlement notice for the settlement in the The Medicines Company (NASDAQ: MDCO) Investor Securities Class Action Lawsuit can be downloaded at: http://shareholdersfoundation.com/case/medicines-company-nasdaq-mdco-investor-securities-class-action-lawsuit-02212014
In order to submit a claim an investor has to submit the claim proof to the class action claim administrator in a timely manner. The deadline to submit the proof with the class administrator is June 13, 2016. The class action administrator for this case is MDCO Securities Litigation.
The lawsuit was originally filed against The Medicines Company over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between February 20, 2013 and February 12, 2014. According to the complaint the plaintiff alleges on behalf of all persons or entities who purchased or otherwise acquired securities of The Medicines Company (NASDAQ: MDCO) between February 20, 2013 and February 12, 2014, that The Medicines Company and certain of its officers and directors violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. More specifically, the plaintiff claims that the defendants made allegedly false and/or misleading statements and/or failed to disclose that Cangrelor, The Medicines Company drug candidate designed to prevent blood clots during heart artery-clearing angioplasty and stenting procedures, did not show superiority to clopidogrel, a competing drug already approved by the U.S. Food and Drug Administration (“FDA”), that The Medicines Company’a CHAMPION clinical trials which compared the efficacy of Cangrelor to clopidogrel were unethically and inappropriately administered including by delaying administration of clopidogrel and lowering its dosage, and that as a result of the foregoing, The Medicines Company’s public statements were materially false and misleading at all relevant times.
Those who purchased NASDAQ: MDCO shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
Leave Your Comments